ArticleKidney medicine
Vascular Access and Risk of Bloodstream Infection Among Older Incident Hemodialysis Patients.
Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- Epidemiology, antimicrobial resistance, and mortality of bloodstream infections in hemodialysis patients: an 11-year retrospective cohort study from southern Saudi Arabia.BMC nephrology · 2026Article
- Hemodialysis Facilities, Vascular Access Surgeons, and Central Venous Catheter Use: A Retrospective Cohort Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026Article
- Latent profile analysis of knowledge, attitude and practice of hospital infection prevention and control among haemodialysis nurses in Sichuan, China: a multicenter study.Frontiers in public health · 2026Article
- Current State and Future Direction of Vascular Access Training in the United States.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Therapeutic Drug Monitoring of Vancomycin in Hemodialysis Patients in a Hospital in North-East Romania.Antibiotics (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE &
objectiveMost new patients with end-stage renal disease (ESRD) initiate hemodialysis (HD) with a central venous catheter (CVC) and later transition to a permanent vascular access with lower infection risk. The benefit of early fistula use in preventing severe infections is incompletely understood. We examined patients' first access and subsequent transitions between accesses during the first year of HD to estimate the risk for bloodstream infection (BSI) associated with incident and time-dependent use of HD access. STUDY
designA retrospective cohort study using enhanced 5% Medicare claims data. SETTING &
participantsNew patients with ESRD initiating HD between January 1, 2011, and December 31, 2012, and having complete pre-ESRD Medicare fee-for-service coverage for 2 years. EXPOSURE: The incident and prevalent use of CVC, graft, or fistula as determined from monthly reports to the Centers for Medicare & Medicaid Services by HD providers. OUTCOME: Incident hospitalization with a primary/secondary diagnosis of BSI ( ANALYTICAL APPROACH: Extended survival analysis accounting for patient confounders.
resultsOf 2,352 study participants, 1,870 (79.5%), 77 (3.3%), and 405 (17.2%) initiated HD with a CVC, graft, and fistula, respectively. During the first year, the incident BSI hospitalization rates per 1,000 person-days were 1.3, 0.8, and 0.3 ( LIMITATIONS: Restricted to an elderly population; potential residual confounding.
conclusionsIncident fistula use was associated with lowest rates of BSI, but the majority of beneficiaries with pre-ESRD insurance initiated HD with a CVC. Strategies are needed to improve pre-ESRD fistula placement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.